A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials

Research output: Contribution to journalReviewResearchpeer-review

Standard

A review of dipeptidyl peptidase-4 inhibitors : Hot topics from randomized controlled trials. / Deacon, Carolyn F.

In: Diabetes, Obesity and Metabolism, Vol. 20, 02.2018, p. 34-46.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Deacon, CF 2018, 'A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials', Diabetes, Obesity and Metabolism, vol. 20, pp. 34-46. https://doi.org/10.1111/dom.13135

APA

Deacon, C. F. (2018). A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism, 20, 34-46. https://doi.org/10.1111/dom.13135

Vancouver

Deacon CF. A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism. 2018 Feb;20:34-46. https://doi.org/10.1111/dom.13135

Author

Deacon, Carolyn F. / A review of dipeptidyl peptidase-4 inhibitors : Hot topics from randomized controlled trials. In: Diabetes, Obesity and Metabolism. 2018 ; Vol. 20. pp. 34-46.

Bibtex

@article{c45ceaaa4f6f4c9fa59bbc37dcb70b75,
title = "A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials",
abstract = "The first clinical study to investigate effects of dipeptidyl peptidase-4 (DPP-4) inhibition was published in 2002, and since then, numerous randomized controlled trials (RCTs) have shown that DPP-4 inhibitors are efficacious, safe and well-tolerated. This review will focus upon RCTs which have investigated DPP-4 inhibitors in patient groups which are often under-represented or excluded from typical phase 3 clinical trials. Large cardiovascular (CV) safety outcome trials in patients with established CV disease have confirmed that DPP-4 inhibitors are not associated with any additional CV risk in these already-at-high-risk individuals, while raising awareness of any uncommon adverse events, such as heart failure hospitalization seen in one of the trials. Studies in patients with kidney disease have shown DPP-4 inhibitors to be efficacious without increasing the risk of hypoglycaemia, irrespective of the degree of renal impairment, while data from the large CV trials as well as smaller RCTs have even pointed towards potential renoprotective effects such individuals. The use of DPP-4 inhibitors with insulin when therapy requires intensification may be beneficial without affecting the incidence or severity of hypoglycaemia, with these effects also being replicated in patients with chronic kidney disease, for whom other agents may not be suitable. Attention is now turning towards exploring the potential utility of DPP-4 inhibitors in other circumstances, including for in-hospital management of hyperglycaemia and in other metabolic disorders. Together, these RCTs raise the possibility that in the future, DPP-4 inhibitors may have a broader use which may extend beyond glycaemic control in the typical type 2 diabetes mellitus (T2DM) patient seen in general practice and may encompass conditions other than T2DM.",
keywords = "Journal Article, Review",
author = "Deacon, {Carolyn F}",
note = "{\circledC} 2018 John Wiley & Sons Ltd.",
year = "2018",
month = "2",
doi = "10.1111/dom.13135",
language = "English",
volume = "20",
pages = "34--46",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - A review of dipeptidyl peptidase-4 inhibitors

T2 - Hot topics from randomized controlled trials

AU - Deacon, Carolyn F

N1 - © 2018 John Wiley & Sons Ltd.

PY - 2018/2

Y1 - 2018/2

N2 - The first clinical study to investigate effects of dipeptidyl peptidase-4 (DPP-4) inhibition was published in 2002, and since then, numerous randomized controlled trials (RCTs) have shown that DPP-4 inhibitors are efficacious, safe and well-tolerated. This review will focus upon RCTs which have investigated DPP-4 inhibitors in patient groups which are often under-represented or excluded from typical phase 3 clinical trials. Large cardiovascular (CV) safety outcome trials in patients with established CV disease have confirmed that DPP-4 inhibitors are not associated with any additional CV risk in these already-at-high-risk individuals, while raising awareness of any uncommon adverse events, such as heart failure hospitalization seen in one of the trials. Studies in patients with kidney disease have shown DPP-4 inhibitors to be efficacious without increasing the risk of hypoglycaemia, irrespective of the degree of renal impairment, while data from the large CV trials as well as smaller RCTs have even pointed towards potential renoprotective effects such individuals. The use of DPP-4 inhibitors with insulin when therapy requires intensification may be beneficial without affecting the incidence or severity of hypoglycaemia, with these effects also being replicated in patients with chronic kidney disease, for whom other agents may not be suitable. Attention is now turning towards exploring the potential utility of DPP-4 inhibitors in other circumstances, including for in-hospital management of hyperglycaemia and in other metabolic disorders. Together, these RCTs raise the possibility that in the future, DPP-4 inhibitors may have a broader use which may extend beyond glycaemic control in the typical type 2 diabetes mellitus (T2DM) patient seen in general practice and may encompass conditions other than T2DM.

AB - The first clinical study to investigate effects of dipeptidyl peptidase-4 (DPP-4) inhibition was published in 2002, and since then, numerous randomized controlled trials (RCTs) have shown that DPP-4 inhibitors are efficacious, safe and well-tolerated. This review will focus upon RCTs which have investigated DPP-4 inhibitors in patient groups which are often under-represented or excluded from typical phase 3 clinical trials. Large cardiovascular (CV) safety outcome trials in patients with established CV disease have confirmed that DPP-4 inhibitors are not associated with any additional CV risk in these already-at-high-risk individuals, while raising awareness of any uncommon adverse events, such as heart failure hospitalization seen in one of the trials. Studies in patients with kidney disease have shown DPP-4 inhibitors to be efficacious without increasing the risk of hypoglycaemia, irrespective of the degree of renal impairment, while data from the large CV trials as well as smaller RCTs have even pointed towards potential renoprotective effects such individuals. The use of DPP-4 inhibitors with insulin when therapy requires intensification may be beneficial without affecting the incidence or severity of hypoglycaemia, with these effects also being replicated in patients with chronic kidney disease, for whom other agents may not be suitable. Attention is now turning towards exploring the potential utility of DPP-4 inhibitors in other circumstances, including for in-hospital management of hyperglycaemia and in other metabolic disorders. Together, these RCTs raise the possibility that in the future, DPP-4 inhibitors may have a broader use which may extend beyond glycaemic control in the typical type 2 diabetes mellitus (T2DM) patient seen in general practice and may encompass conditions other than T2DM.

KW - Journal Article

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85041084254&partnerID=8YFLogxK

U2 - 10.1111/dom.13135

DO - 10.1111/dom.13135

M3 - Review

C2 - 29364584

VL - 20

SP - 34

EP - 46

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -

ID: 189765779